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OBJECTIVE — To determine whether the association between depressive symptoms and
glycemic control is mediated by blood glucose monitoring (BGM).
RESEARCH DESIGN AND METHODS — A total of 276 adolescents with type 1 dia-
betes (mean age  SD, 15.6  1.4 years) completed a measure of depressive symptoms. Socio-
demographic and family characteristics were obtained from caregivers. BGM frequency and
glycemic control were obtained at a clinic visit.
RESULTS — Separate regression analyses revealed that depressive symptoms were associated
withlowerBGMfrequency(B0.03;P0.04)andhigherA1C(B0.03;P0.05)andthat
lowerBGMfrequencywasassociatedwithhigherA1C(B0.39;P0.001).Withdepressive
symptomsandBGMfrequencyincludedtogether,onlyBGMfrequencywasassociatedwithA1C
and depressive symptoms became nonsigniﬁcant (B  0.02; P  0.19). The Sobel test was
signiﬁcant (Z  1.96; P  0.05) and showed that 38% of the depression-A1C link can be
explained by BGM.
CONCLUSIONS — BGM is a mediator between depressive symptoms and glycemic control
in adolescents with type 1 diabetes.
Diabetes Care 32:804–806, 2009
A
dolescents with type 1 diabetes
have elevated risk for poor blood
glucose monitoring (BGM) adher-
ence and suboptimal glycemic control
(1,2). Adolescents also experience in-
creased risk for depressive symptoms (3–
5), which are associated with higher A1C
values (4,5). Although BGM nonadher-
ence and depressive symptoms both
contribute to higher A1C values, little is
known about their collective associa-
tion with glycemic control. Previous
studies in adults have tested the media-
tional role of adherence (6). We aimed
to evaluate whether the depressive
symptoms–glycemic control link is me-
diated by BGM.
RESEARCH DESIGN AND
METHODS— Adolescents with type
1 diabetes were eligible for this study if
they did not have a major psychiatric/
neurocognitive disorder that would in-
hibit ability to participate, a signiﬁcant
medical disease other than type 1 diabe-
tes, or the inability to read or understand
English. At the northeastern clinical site,
173eligibleadolescentswereapproached
and 126 participated. At the midwestern
site, 166 eligible adolescents were ap-
proached and 150 participated. All study
procedures were approved by the institu-
tional review board at each site. Written
informed consent from caregivers and
consent/assent from adolescents were
obtained.
Measures
Youth depressive symptoms were as-
sessed using the Children’s Depression
Inventory (CDI) (7), a self-report ques-
tionnaire consisting of 27 items. Higher
scores indicate more depressive symp-
tomatology(4,7).Therewasahighdegree
of internal consistency in this sample (co-
efﬁcient 0.86).
BGM frequency was obtained via
meterdownloadorself-report.Ofthe276
adolescents, 158 provided meters for
downloading; their daily BGM frequency
was correlated with (r  0.66; P 
0.0001) and similar to their self-report
(daily meter mean 4.15 and self-report
mean4.26).Becauseofthisself-reportin-
ﬂation, 118 adolescents with only self-
report data had their values adjusted by
multiplying them by 0.97 (4.15/4.26).
There were no differences between ado-
lescents with or without meter download
on A1C or CDI scores (P values 0.05).
Adolescents at the northeastern clini-
cal site had A1C determined by high-
performance liquid chromatography
(reference range 4.0–6.0%) (Tosoh 2.2;
Tosoh, Foster City, CA). Adolescents at
themidwesternclinicalsitehadA1Cmea-
suredbyDCA2000(4.3–5.7%)(Bayer,
Tarrytown, NY). A1C values obtained
from the laboratory and by DCA 2000
have shown high agreement (8).
Duration of diabetes and mode of in-
sulin administration were obtained from
chart review. Family demographic data
were obtained from the caregiver.
Statistical analyses
We conducted multivariate analyses (9)
using general linear modeling to test the
hypothesis that BGM would mediate the
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link. First, the effect of depressive symp-
toms on BGM frequency was tested. Sec-
ond,theeffectofdepressivesymptomson
A1C values was tested. Third, BGM fre-
quency was added to test its mediational
role. The Sobel test examined the signiﬁ-
canceofthemediationaleffect,andapost
hoc model of interactions was tested. Co-
variates (age, sex, ethnicity, diabetes du-
ration, and mode of insulin delivery;
caregiver education level, insurance sta-
tus, and marital status; site; and availabil-
ityofmeterdownload)wereincludedin
all models. Analyses were conducted
using SAS (version 9.1; SAS Institute,
Cary, NC).
RESULTS— Table 1 displays charac-
teristics of the total sample by site. The
data for the ﬁrst model (depressive symp-
toms plus covariates 3 BGM) were sig-
niﬁcant. Lower levels of BGM frequency
were associated with more depressive
symptoms(B0.03;P0.02),insulin
delivery via injections (B  0.85; P 
0.001), less caregiver education (B 
0.53; P  0.01), participation at the
midwestern site (B  0.85; P  0.005),
and older age (B  0.34; P  0.001).
The data for the second model (de-
pressivesymptomspluscovariates3gly-
cemic control) were signiﬁcant. Higher
A1Cvalueswereassociatedwithmorede-
pressive symptoms (B  0.03; P  0.05),
longer diabetes duration (B  0.07; P 
0.007), insulin delivery via injections
(B  0.74; P  0.001), and single care-
giver marital status (B  0.63; P  0.02).
The data for the third model (depres-
sive symptoms plus BGM frequency plus
covariates 3 glycemic control) were sig-
niﬁcant; however, with depressive symp-
toms and BGM frequency in the model,
theeffectofdepressivesymptomsbecame
nonsigniﬁcant (B  0.02; P  0.19).
Higher A1C values were associated with
lower levels of BGM frequency (B 
0.39; P  0.001), longer duration of
diabetes(B0.05;P0.03),singlecare-
giver marital status (B  0.58; P  0.02),
and participation at the northeastern site
(B0.61;P0.05).TheSobeltest,eval-
uating the magnitude of mediation, was
signiﬁcant(Z1.96;P0.05);37.5%of
the depressive symptoms–glycemic con-
trol link was explained by BGM. A post
hoc model included interactions between
signiﬁcant covariates and BGM fre-
quency; however, none were signiﬁcant,
indicatingthatcovariatesweredirectlyas-
sociated with glycemic control.
CONCLUSIONS— Results from this
cross-sectional analysis indicate that the
depressive symptoms–glycemic control
link is partially explained by BGM. Previ-
ous research highlights that depressive
symptoms are associated with lower self-
efﬁcacy,negativeattributions,anddimin-
ished ability to concentrate (10,11).
Adolescents with type 1 diabetes and ele-
vated depressive symptoms may have
trouble initiating tasks for diabetes man-
agement, carrying them out, and believ-
ing they will be effective.
The primary implication is that
careful monitoring of depressive symp-
toms is warranted. This recommenda-
tion has been advocated previously in
individual studies (4,5) and by the
American Diabetes Association task
force (12); however, these ﬁndings
highlight the potential for negative con-
sequences with regard to diabetes man-
agement and outcomes when elevated
depressive symptoms exist. Second,
once identiﬁed, depressive symptoms
needtobetreated.Thereisstrongempirical
evidence that cognitive-behavioral treat-
ments are effective in reducing depressive
symptomsinadolescents(13);thus,thisap-
pears to be a viable option, especially if the
diabetes-speciﬁc context is considered.
Third, straightforward attempts to promote
BGM adherence may prove ineffective.
Phased interventions may be most appro-
priate; one should attempt to reduce de-
pressive symptoms before attempting to
promote BGM adherence.
Limitations include the inability to
rule out bidirectional relationships be-
tweendepressivesymptomsandglycemic
control in these cross-sectional data. De-
pressive symptoms were measured by
self-report using CDI, providing an indi-
cation of clinically signiﬁcant levels of de-
pressive symptoms and not a diagnosis.
Adolescents were predominantly white
withmarriedcaregivers;ﬁndingsmaynot
generalize to more diverse families. Fi-
nally, we only examined BGM adherence.
While previous studies highlight the
importance of BGM frequency as an in-
dicator of overall adherence and glyce-
mic outcomes (14,15), future studies
should examine multiple dimensions of
adherence.
In sum, adolescents with type 1 dia-
betes who experience elevated depressive
symptoms are also likely to experience
problems with BGM. When that occurs,
suboptimal glycemic control likely re-
sults. Continued surveillance of depres-
sive symptoms is suggested, and targeted
interventionsfortheseadolescentswithin
a diabetes-speciﬁc framework appear
warranted.
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